AivoCode

AivoCode is an emerging biotech startup pioneering novel platform technologies to improve treatment and management of neurological diseases by promoting neuroprotection and blocking neuroinflammation.

biotechhealth AIneurodegenerative diseases

Visit website

StageSeed

Raised$5.6M

Employees2

LocationSan Diego, CA

About

AivoCode is a neuroscience-focused biotech startup that is pioneering the development of innovative and broad platform technologies to improve the treatment and management of neurological diseases such as brain injury, Alzheimer’s disease and other neurodegenerative disorders.

Product

Value proposition: Developing broad platform technologies and therapeutic candidates to protect neurons, reduce neuroinflammation and oxidative stress, and preserve cognitive and motor function in brain injuries and neurodegenerative diseases.
Target customers: pharmaceutical/biotech companies, research institutions, and potential collaborators in neurodegenerative disease drug development

Founders

Sajid Hussain (or Sazid Hussain) — Co-Founder & Chief Scientific Officer
Erkki Ruoslahti — Co-Founder & Executive Chairman
Aman Mann — Co-Founder & CEO

Products

therapeutic antibodies (targeting early AD vascular target)neuroprotective assetsplatform technologies for molecular zip codes screening

Key features

unbiased screening to identify molecular zip codes in diseased brain regionsearly intervention targets in Alzheimer’s diseaseneuroprotection and anti-inflammatory/antioxidant strategiestherapeutic antibodies development for neurodegenerative targetsbroad platform technologies for brain disease treatment

Technologies

unbiased screeningtherapeutic antibodiesneuroinflammation modulationneuroprotectionplatform technology for disease-region targeting

Target conditions

Alzheimer’s diseaseoptic neuropathiesglaucomaneuroinflammatory conditionsbrain injuriesneurodegenerative disorders

Care settings

research laboratory

Traction metrics

early-stage biotech startuplead candidate in neuroprotectionfocus on Alzheimer’s disease and optic neuropathies (Glaucoma)

Investors

National Science FoundationHHSSignite PartnersHana Financial GroupGGV CapitalSixteenth Street Capital

News

AivoCode receives a $2.5M SBIR grant to develop a novel... · 2026-04-06T00:00:00.000Z
Researchers discover a compound that could change the treatment of traumatic brain injuries – IQAC – Institut de Química Avançada de Catalunya – CSIC · 2025-10-07T08:01:31.000Z
Stem cells retain inflammatory memory, affecting regeneration and... · 2025-09-19T00:00:00.000Z
Todd Rubinstein's Post - LinkedIn · 2024-09-23T00:00:00.000Z
Nucleate New York Returns to BlueRock for 4th Year - LinkedIn · 2026-04-24T00:00:00.000Z